Showing results (81-90 of 130) with videos related to
Sort By:
Pageof 13
European Journal of Cancer (Oxford, England : 1990)|June 2, 2021
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker studyVincenza Conteduca, Daniel Wetterskog, Elena Castro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerGerhardt Attard, Alison H M Reid, Roger A'Hern, et al.The New England Journal of Medicine|September 21, 2020
Survival with Olaparib in Metastatic Castration-Resistant Prostate CancerMaha Hussain, Joaquin Mateo, Karim Fizazi, et al.Future Oncology (London, England)|February 5, 2014
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancerL Rhoda Molife, Aurelius Omlin, Rob J Jones, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2011
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignanciesDavid Olmos, Douglas Barker, Rohini Sharma, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2005
Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group studyJorge Aparicio, José R Germà, Xavier García del Muro, et al.European Urology Open Science|February 22, 2024
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 StudyChiara Casadei, Emanuela Scarpi, Vincenza Conteduca, et al.European Urology|September 10, 2020
Apalutamide and Overall Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2024
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE TrialFred Saad, Egils Vjaters, Neal Shore, et al.The Lancet. Oncology|February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trialMatthew R Smith, Howard I Scher, Shahneen Sandhu, et al.Pageof 13